Business Context and Reporting Period
Company: HALOZYME THERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date: March 3, 2010
Subject: Regulation FD Disclosure updating investor presentation slides regarding a partnership with F. Hoffmann-La Roche, Ltd.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a disclosure of non-financial operational updates.
Material Changes
- Product Candidate Identification: The filing clarifies that the second product candidate under Halozyme's existing partnership with F. Hoffmann-La Roche, Ltd. is a subcutaneous formulation of MabThera (rituximab).
- Market Context: MabThera is approved for non-Hodgkin's lymphoma (NHL). The filing notes an estimated 66,000 new NHL cases in the U.S. and 125,000 worldwide in 2009.
- Document Update: Slides 11 and 39 from a January 11, 2010 investor presentation are being updated to reflect this specific product identity.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing references forward-looking statements and associated risks found on page 2 of the January 11, 2010 presentation.
- Regulatory Status: The information is furnished under Item 7.01 and is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934, nor will it be incorporated by reference into registration statements unless specifically identified.
- Clinical Trials: Additional information regarding the Phase 1 subcutaneous MabThera clinical trial is available via clinicaltrials.gov and roche-trials.com.
Investor Verification Checklist
- Verify the specific details of the Phase 1 subcutaneous MabThera clinical trial on clinicaltrials.gov.
- Review the full January 11, 2010 investor presentation (specifically page 2) for the complete list of risks and forward-looking statements referenced in this filing.
- Confirm the current status of the partnership agreement with F. Hoffmann-La Roche, Ltd. regarding the subcutaneous formulation.